Skip to main content

Susan Kim

Equibles does not estimate personal net worth.

About Susan Kim

Earlier roles on record: CFO at Pacific Biosciences Of California, Inc. (PACB) until December 6, 2024. Pacific Biosciences Of California, Inc. reported in an 8-K filed November 7, 2024 that Susan Kim resigned as Chief Financial Officer, effective December 6, 2024. Susan Kim has spoken on 16 earnings calls across 1 company, most recently for Pacific Biosciences Of California, Inc. on November 7, 2024. The companies whose calls Susan Kim spoke on are classified in the Healthcare sector.

“On November 5, 2024, Susan Kim notified the Company that she is voluntarily resigning as Chief Financial Officer of the Company effective on December 6, 2024, to accept a position at another organization.”
Pacific Biosciences Of California, Inc. Form 8-K, filed November 7, 2024 · Read the filing

Susan Kim on recent calls

“I'm incredibly proud of what we've accomplished over the past four years, and I'm excited for PacBio's future. I am confident that under Christian's leadership, the team will continue to make tremendous strides in its mission to better human health through the promise of genomics.”
CFO, Pacific Biosciences Of California, Inc. Q3 FY2024 Earnings Call ·
“I will be discussing non-GAAP results, which include non-cash stock-based compensation expense. I encourage you to review a reconciliation of GAAP to non-GAAP financial measures in our earnings press release.”
CFO, Pacific Biosciences Of California, Inc. Q2 FY2024 Earnings Call ·
“As previously mentioned, we reported $38.8 million in product, service, and other revenue in the first quarter of 2024, compared to $38.9 million in the first quarter of 2023.”
CFO, Pacific Biosciences Of California, Inc. Q1 FY2024 Earnings Call ·
“As discussed, we reported $58.4 million in product, service, and other revenue in the fourth quarter of 2023, which represented an increase of 113% from $27.4 million in the fourth quarter of 2022.”
CFO, Pacific Biosciences Of California, Inc. Q4 FY2023 Earnings Call ·
“As discussed, we are pleased to have reported $55.7 million in product, service, and other revenue in the third quarter of 2023, which represented an increase of 72% from $32.3 million in the third quarter of 2022.”
CFO, Pacific Biosciences Of California, Inc. Q3 FY2023 Earnings Call ·

Affiliation history

Company network

Recent activity

Show 5 earlier activities